Takanori Maejima
3PUBLICATIONS
19CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (3)
Sort by Publication Date:
|Nov 25, 2024
Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models.Funda Meric-Bernstam, Erkan Yuca, Kurt W Evans
|Feb 12, 2022
DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody-Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models.Michiko Yamato, Jun Hasegawa, Takanori Maejima
|Aug 20, 2021
Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells.Daisuke Okajima, Satoru Yasuda, Takanori Maejima
Pageof 1
Frequent Collaborators
2 joint publications
Toshinori Agatsuma
1 joint publications
Tadashi Toki
1 joint publications
Kazuyoshi Kumagai
1 joint publications
Funda Meric-Bernstam
1 joint publications
Erkan Yuca
1 joint publications
Kurt W Evans
1 joint publications
Ming Zhao
1 joint publications
Tsuyoshi Karibe
1 joint publications
Maria Gabriela Raso
1 joint publications
Ximing Tang
